|
9 |
16 |
25 |
| Male |
8 |
11 |
19 |
| Indigenous |
3 |
9 |
11 |
| HIV |
2 |
0 |
2 |
| Clinical Diagnoses |
n = 8 |
n = 16 |
n = 24 |
| Meningitis |
0 |
0 |
0 |
| Ocular |
1 |
0 |
1 |
| Meningovascular |
1 |
1 |
2 |
| Dementia |
4 |
10 |
14 |
| Psychosis |
1 |
2 |
3 |
| Tabes Dorsalis |
1 |
2 |
3 |
| Seizures |
2 |
2 |
4 |
| Laboratory |
|
|
|
| Number of reactive serum RPR |
9 |
10 |
19 |
| Median RPR titre |
1:128 (1:2–1:512) |
1:4 (1:1–1:16) |
1:8 (1:1–1:512) |
| Number of CSF examinations |
9 |
16 |
25 |
| Number of positive CSF VDRL (≥ 1:1) |
9 |
0 |
9 |
| Number of reactive CSF TPPA |
8 |
2 |
10 |
| Number of reactive CSF FTA |
8 |
4 |
12 |
| Number with high WCC in CSF (WCC > 5 cell/microL) |
5 (median 26cell/microL, range 7-45cell/microL) |
2 (range 10-21cell/microL) |
7 (median 21 cell/microL, range 7–45 cell/microL) |
| Number with high CSF Protein (Protein > 0.50 mg/L) |
6 (median 1.08mg/L, range 0.68–1.37mg/L) |
16 (median 0.725mg/L, range 0.57–1.37mg/L) |
22 (median 0.77mg/L, range 0.57–1.37mg/L) |
| Management |
n = 9 |
n = 16 |
n = 25 |
| Treatment for NS |
9 |
6 |
15 |
